Balance Sheet Insights: Coherus Biosciences Inc (CHRS)’s Debt-to-Equity and Long-Term Debt/Eq Ratios

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Coherus Biosciences Inc (NASDAQ: CHRS) closed at $0.78 down -1.27% from its previous closing price of $0.79. In other words, the price has decreased by -$1.27 from its previous closing price. On the day, 1.71 million shares were traded. CHRS stock price reached its highest trading level at $0.8125 during the session, while it also had its lowest trading level at $0.78.

Ratios:

For a deeper understanding of Coherus Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.07 and its Current Ratio is at 1.21.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on August 16, 2024, Downgraded its rating to Neutral and sets its target price to $1.50 from $4 previously.

On November 17, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $11.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 22 ’23 when Lanfear Dennis M sold 223,100 shares for $2.02 per share. The transaction valued at 449,770 led to the insider holds 731,693 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CHRS now has a Market Capitalization of 93318736 and an Enterprise Value of 200780528. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.29. Its current Enterprise Value per Revenue stands at 0.652 whereas that against EBITDA is -1.411.

Stock Price History:

Over the past 52 weeks, CHRS has reached a high of $3.73, while it has fallen to a 52-week low of $0.79. The 50-Day Moving Average of the stock is -29.89%, while the 200-Day Moving Average is calculated to be -56.63%.

Shares Statistics:

For the past three months, CHRS has traded an average of 2.22M shares per day and 1908160 over the past ten days. A total of 112.22M shares are outstanding, with a floating share count of 110.58M. Insiders hold about 4.02% of the company’s shares, while institutions hold 68.94% stake in the company. Shares short for CHRS as of 1728950400 were 29853066 with a Short Ratio of 13.45, compared to 1726185600 on 25091785. Therefore, it implies a Short% of Shares Outstanding of 29853066 and a Short% of Float of 30.240000000000002.

Most Popular